APN – Aspen Pharmacare Holdings Limited – Trading statement
Aspen Pharmacare Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number 1985/002935/06)
Share code: APN & ISIN: ZAE000066692
Aspen shareholders are hereby advised that, diluted normalised headline earnings per share (“DNHEPS”) from continuing operations, headline earnings per share and earnings per share for the 6 months ended 31 December 2012, are expected to exceed those reported in the comparative period, ended 31 December 2011, within the following ranges:
|DNHEPS from continuing operations||21% to 25%||1|
|Headline earnings per share||15% to 19%||2|
|Earnings per share||5% to 9%||3|
1. DNHEPS from continuing operations comprises diluted headline earnings per share adjusted for transaction costs, restructure costs and foreign exchange movements on transaction accounting. DNHEPS is the primary measure used by management to assess Aspen’s underlying operating performance.
2. The growth in headline earnings per share has been diluted by the effect of an increase in the weighted average number of ordinary shares in issue as a consequence of the conversion of 17.6 million preference shares into an equivalent number of ordinary shares on 28 June 2012.
3. The growth in earnings per share has been diluted as a result of capital profits on the disposal of discontinued businesses and products in the prior year and the effect of an increase in the weighted average number of ordinary shares in issue as a consequence of the conversion of 17.6 million preference shares into an equivalent number of ordinary shares on 28 June 2012.
The financial results on which this trading announcement is based have not been reviewed or reported on by Aspen`s external auditors.
Aspen`s interim results for the 6 months ended 31 December 2012 are scheduled to be published on SENS on 7 March 2013.
21 February 2013
Sponsor: Investec Bank Limited